Tetrabenazine<wbr/>-d<sub>6</sub>

Tetrabenazine-d6

CAT N°: 26811
Price:

From 85.00 72.25

Tetrabenazine-d6 is intended for use as an internal standard for the quantification of tetrabenazine (Item No. 20380) by GC- or LC-MS. Tetrabenazine is an inhibitor of vesicular monoamine transporter 2 (VMAT2) that is selective over VMAT1 (Kis = 97 and >20,000 nM, respectively, in a serotonin uptake assay).{26973} It dose-dependently reduces levels of the monoamines norepinephrine (Item No. 16673), dopamine (Item No. 21992), and serotonin (5-HT; Item No. 14332) in rat brain and has been used to induce depressive-like behavior in animal models.{47227,47228} Tetrabenazine (5 mg/kg) improves performance in balance beam and rotarod tests and prevents decreases in the number of striatal medium spiny neurons (MSNs) in a YAC128 transgenic mouse model of Huntington’s disease.{47229} Formulations containing tetrabenazine have been used in the treatment of chorea associated with Huntington’s disease.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • rel-1,3R,4,6,7,11bR-hexahydro-9,10-di(methoxy-d3)-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one
  • Correlated keywords
    • Austedo Deutetrabenazine SD809 SD-809 deuterated deuterium GCMS LCMS NSC 169886 172187 Ro 1-9569 19569 NSC169886 NSC172187 9569 Ro19569 VMAT-1 2 5HT YAC-128
  • Product Overview:
    Tetrabenazine-d6 is intended for use as an internal standard for the quantification of tetrabenazine (Item No. 20380) by GC- or LC-MS. Tetrabenazine is an inhibitor of vesicular monoamine transporter 2 (VMAT2) that is selective over VMAT1 (Kis = 97 and >20,000 nM, respectively, in a serotonin uptake assay).{26973} It dose-dependently reduces levels of the monoamines norepinephrine (Item No. 16673), dopamine (Item No. 21992), and serotonin (5-HT; Item No. 14332) in rat brain and has been used to induce depressive-like behavior in animal models.{47227,47228} Tetrabenazine (5 mg/kg) improves performance in balance beam and rotarod tests and prevents decreases in the number of striatal medium spiny neurons (MSNs) in a YAC128 transgenic mouse model of Huntington’s disease.{47229} Formulations containing tetrabenazine have been used in the treatment of chorea associated with Huntington’s disease.

We also advise you